Skip to content

Source filing unavailable

Q3 2012 · —
Revenue$175.52M+139.5% vs Q3 2011+41.3% vs Q2 2012
Net Income$33.21M+2.2% vs Q3 2011+22.3% vs Q2 2012
EPS Diluted$0.55−20.3% vs Q3 2011+22.2% vs Q2 2012
Gross Profit$141,501,000+107.1%
Operating Income$55,300,000+64.1%
Operating Cash Flowderived$44,143,000−4.1%
Free Cash Flowderived$41,644,000−8.9%
Margins · derived
Gross margin80.6%−12.6 pt vs Q3 2011
Operating margin31.5%−14.5 pt vs Q3 2011
Net margin18.9%−25.4 pt vs Q3 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2012Q3 2011Q3 2010
Revenue$175.52M$73.29M$73.29M
Net Income$33.21M$32.48M$32.48M
EPS Diluted$0.55$0.69$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR